Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Michael Pfreundschuh, Ulrich Kaiser et al.|SpringerPlus|2014Cited by 10
Interdisciplinary guideline on diagnosis, therapy, and follow-up of adult patients with monoclonal gammopathy of undetermined significance or multiple myelomaPiechotta, Nicole Skoetz, Lukas John et al.|Unknown|2020Cited by 0